EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting

Michael Seiberl, Julia Feige, Patrick Hilpold, Wolfgang Hitzl iD, Lukas Machegger, Arabella Buchmann iD, Michael Khalil iD, Eugen Trinka, Andrea Harrer iD, Peter Wipfler iD, Tobias Moser iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24044067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Michael Seiberl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, European Referen…. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Gesellschaft mbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Serum neurofilament light chain (sNfL) is an intensely investigated biomarker in multiple sclerosis (MS). The aim of this study was to explore the impact of cladribine (CLAD) on sNfL and the potential of sNfL as a predictor of long-term treatment response. Data were gathered from a prospective, real-world CLAD cohort. We measured sNfL at baseline (BL-sNfL) and 12 months (12Mo-sNfL) after CLAD start by SIMOA. Clinical and radiological assessments determined fulfilment of “no evidence of disease activity” (NEDA-3). We evaluated BL-sNfL, 12M-sNfL and BL/12M sNfL ratio (sNfL-ratio) as predictors for treatment response. We followed 14 patients for a median of 41.5 months (range 24.0–50.0). NEDA-3 was fulfilled by 71%, 57% and 36% for a period of 12, 24 and 36 months, respectively. We observed clinical relapses in four (29%), MRI activity in six (43%) and EDSS progression in five (36%) patients. CLAD significantly reduced sNfL (BL-sNfL: mean 24.7 pg/mL (SD ± 23.8); 12Mo-sNfL: mean 8.8 pg/mL (SD ± 6.2); p = 0.0008). We found no correlation between BL-sNfL, 12Mo-sNfL and ratio-sNfL and the time until loss of NEDA-3, the occurrence of relapses, MRI activity, EDSS progression, treatment switch or sustained NEDA-3. We corroborate that CLAD decreases neuroaxonal damage in MS patients as determined by sNfL. However, sNfL at baseline and at 12 months failed to predict clinical and radiological treatment response in our real-world cohort. Long-term sNfL assessments in larger studies are essential to explore the predictive utility of sNfL in patients treated with immune reconstitution therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisHumansCladribineProspective StudiesIntermediate FilamentsNeurofilament ProteinsBiomarkersRecurrence

Stichwörter der Autor:innen

NfLbiomarkersdisease activityimmune reconstitutionmultiple sclerosistreatment response

Substanzen

CladribineNeurofilament ProteinsBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, European Reference Network EpiCARE, 5020 Salzburg, Austria.
  • Research Management (RM): Biostatistics and Publication of Clinical Studies Team, Paracelsus Medical University, 5020 Salzburg, Austria.
  • Department of Ophthalmology and Optometry, Paracelsus Medical University, 5020 Salzburg, Austria.
  • Research Program Experimental Ophthalmology and Glaucoma Research, Paracelsus Medical University, 5020 Salzburg, Austria.
  • Division of Neuroradiology, Christian Doppler Medical Center, Paracelsus Medical University, 5020 Salzburg, Austria.
  • Department of Neurology, Medical University of Graz, 8036 Graz, Austria.

ORCID-Profile: Wolfgang Hitzl, Arabella Buchmann, Michael Khalil, Andrea Harrer, Peter Wipfler, Tobias Moser

Förderung

  • Merck Gesellschaft mbH

Zitieren

APA

Seiberl, M., Feige, J., Hilpold, P., Hitzl, W., Machegger, L., Buchmann, A., Khalil, M., Trinka, E., Harrer, A., Wipfler, P., & Moser, T. (2023). Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24044067

Vancouver

Seiberl M, Feige J, Hilpold P, Hitzl W, Machegger L, Buchmann A, et al. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24044067

BibTeX
@article{Seiberl2023,
  author = {Seiberl, Michael and Feige, Julia and Hilpold, Patrick and Hitzl, Wolfgang and Machegger, Lukas and Buchmann, Arabella and Khalil, Michael and Trinka, Eugen and Harrer, Andrea and Wipfler, Peter and Moser, Tobias},
  title = {Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24044067}
}
Kostenlos starten →